Login to Your Account

Clinic Roundup

Tuesday, August 16, 2011
• ICo Therapeutics Inc., of Vancouver, British Columbia, said an investigator-sponsored Phase II trial of antisense drug iCo-007 for diabetic macular edema was initiated in the U.S. ICo-007, discovered by Isis Pharmaceuticals Inc., targets c-Raf kinase.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription